Introduction
Disease-modifying therapies (DMT) are moderately effective at reducing relapse rates, slowing disability progression, decreasing brain lesion accumulation and delaying conversion of clinically isolated syndrome (CIS) to relapsing-remitting multiple sclerosis (RRMS). 1, 2 Patients who persist on therapy have been reported to undergo fewer hospital admissions and to incur lower MS-related healthcare costs when compared with patients who discontinue or never initiate a DMT. 3 Until recently, the injectable compounds IFNβ-1a IM, IFNβ-1a SC, IFNβ-1b and glatiramer acetate were the only DMTs available. Despite evidence from controlled studies supporting their efficacy, the uptake of, and persistence on, these therapies has been limited by their parenteral route of administration, side effects and a perceived lack of efficacy on the part of the patient brought about by the unpredictable, intermittent nature of relapses. 4, 5 Studies have shown that persistence on injectable DMTs is surprisingly short. It has been reported that between 4% and 57% of patients discontinue treatment within 12 months of DMT initiation, with average persistence on therapy ranging from approximately 0.6 to 2.8 years, and significant differences existing across countries and between nationalities. [5] [6] [7] [8] [9] [10] [11] Fingolimod, the first widely available orally administered DMT, has been shown to be superior to both placebo and IFNβ-1a IM in reducing relapse activity and brain lesion accumulation. [12] [13] [14] Given it lacks some of the tolerability issues inherent in the injectable therapies, the introduction of fingolimod brings with it the prospect of improved treatment tolerance, increased treatment persistence and, potentially, improved patient outcomes. However, no large prospective studies have assessed patterns of treatment utilisation and switching since the introduction of fingolimod. The few published studies that have are retrospective in nature, with limited follow-up. 15, 16 This study aims to characterise how the introduction of fingolimod has affected treatment persistence, treatment utilisation and predictors of treatment discontinuation in an international, prospective, observational cohort of patients with CIS and early RRMS.
Methods

Ethics statement
The MSBase registry 17 (registered with WHO ICTRP, ID ACTRN12605000455662) was approved by the Melbourne Health Human Research Ethics Committee. Human Research Ethics Committee approval, or exemptions according to local regulations, as well as written informed consent from patients to participate in the MSBase registry, was obtained at each participating site.
Database
The MSBase Incident Study (MSBASIS) is an international, observational cohort study of patients seen from CIS onset, from 69 treatment centres across 19 countries (see Supplementary Table 1 ). The study commenced in December 2004. Data extraction took place on 20 January 2015. MSBASIS requires a minimum baseline dataset of MS-related outcomes to be recorded at first visit, as well as a minimum dataset to be provided at each follow-up visit, which must occur at least annually. Patient datasets were recorded in or near real-time using the iMed electronic patient record system.
Patients and procedures
A patient was considered eligible for the study if a participating neurologist confirmed the diagnosis of CIS within 12 months of CIS onset using the 2005 or 2010 McDonald diagnostic criteria as per the year of diagnosis. Patients were excluded from the study if they had a diagnosis of primary progressive MS, were prescribed fingolimod as part of a clinical trial or were prescribed mitoxantrone or an oral DMT other than fingolimod (the latter exclusion being due to insufficient commencements per therapy for statistical analysis). The minimum baseline dataset included date of CIS onset, clinical presentation, Kurtzke Expanded Disability Status Scale (EDSS) and functional system scores, and a cerebral magnetic resonance imaging (MRI) scan available within 12 months of CIS onset. The minimum dataset collected at each follow-up appointment included date of visit, date of onset and duration of any relapses, DMT commencement and cessation dates, glucocorticoid therapy for relapses and EDSS scores including functional system scores. Reasons for treatment discontinuation were recorded for a proportion of treatment cessations. Online EDSS competency certification was required at each participating centre. The quality assurance procedures are described elsewhere. 4 For the purpose of this analysis, the start of the post-oral treatment epoch was determined for each country as the date of the first fingolimod initiation outside a clinical trial in patients within MSBASIS. Duration of each treatment within either of these epochs was specified, with left-and right-side censoring introduced to categorise the treatment extending across both epochs. 18 Definitions A relapse was defined as occurrence of new symptoms or exacerbation of existing symptoms persisting for >24 h, in the absence of concurrent illness or fever, and occurring at least 30 days after a previous relapse. Baseline annualised relapse rate (ARR) was calculated as the number of relapses experienced prior to treatment divided by the years between CIS onset and treatment commencement. The number of relapses in the 6 months preceding treatment discontinuation or censoring was noted. Change in EDSS was defined as the difference in EDSS scores between the earliest and latest visits within the treatment period. Treatment cessation was defined as a period of 90 or more days without treatment after a DMT was initiated. Treatment switch was defined as any DMT commencement following a previously discontinued therapy. A delayed continuation was defined as stopping a DMT for more than 90 days only to reinitiate the same DMT.
Statistical analysis
In order to analyse treatment duration, patient data were censored at the most recent visit date. Treatment persistence for all initiation events was visualised using the Kaplan-Meier method. The formal statistical evaluation of the effect of treatment epoch and other predictors of treatment persistence was conducted with a two-step conditional risk set model, with the final multivariable model built based on the outcomes of a series of univariable models. 19 A variation of the Andersen-Gill model (a proportional hazards model with robust variance estimation), the conditional risk set model allows for multiple events and adjusts for the event dependence (such as the individual propensity to treatment discontinuations).
Hazard proportionality was assessed in both the univariable and multivariable models by analysis of scaled Schoenfeld residuals. Interactions between epoch and all other variables were tested to determine whether the introduction of fingolimod had altered predictors of treatment discontinuation. Fisher's exact test was used to test for differences in the recorded reasons for treatment discontinuation between DMTs. All reported p-values are two-tailed and p<0.05 was considered significant for each analysis. All analyses were performed using Stata version 12.0 (StataCorp, College Station, Texas).
Results
Patient demographics and treatment characteristics
A total of 4111 patients were included in the study; Figure 1 summarises patient disposition in relation to treatment epoch and exclusion criteria. Of these, a total of 2640 patients were prescribed at least one DMT over a median follow-up period of 4.8 years (interquartile range (IQR): 2.4, 7.1), with 71.4% of first treatment commencements occurring prior to the introduction of oral therapies and 28.6% occurring after fingolimod became available. Baseline characteristics for patients at first treatment commencement for each DMT are summarised in Table 1 . Patients initiating therapy with natalizumab appeared younger at symptom onset and treatment start, had higher relapse and MRI activity and were less likely to start therapy during CIS when compared with patients on other treatments. Conversely, patients were more likely to start therapy during CIS with IFNβ-1a IM.
We Table 2 summarises the treatment discontinuation events by sex, location, DMT identity, EDSS score at treatment start and baseline MRI results.
Predictors of treatment discontinuation
Univariable analyses revealed that sex, location, treatment identity, pre-/post-oral epoch, age at treatment start, relapse activity and EDSS step at treatment start were all associated with changes in treatment discontinuation rates and were therefore included in the multivariable model. The multivariable analysis revealed that patients were significantly more likely to discontinue treatment in the post-oral epoch (Figure 2 The multivariable model also demonstrated that male sex was predictive of a decreased risk of treatment discontinuation (Figure 2 (c)), as was older age at treatment start. An EDSS score of greater than 4 at treatment start when compared with an EDSS score of zero was associated with a greater risk of treatment discontinuation. Patients who discontinued therapy were more likely to have experienced relapses within the 6 months preceding treatment discontinuation, while patients being treated in all locations except for the Netherlands and Canada had a lower risk of treatment discontinuation when compared with patients in Australia. Table 3 and Table 4 , respectively.
Reasons for treatment discontinuation and switching
Recording of categorically described reasons for treatment discontinuation is not a mandatory part of the MSBASIS observational protocol, but data were available for 54.8% of discontinuations. Table 5 reports the reasons for treatment discontinuation across all therapies, showing that an adverse event or lack of tolerance was the most common reason for treatment discontinuation among patients on IFNβ-1a SC, IFNβ-1b and glatiramer acetate (31.0-36.0% of recorded discontinuations) while patients on IFNβ-1a appeared more likely to discontinue treatment due to a lack of improvement (30.2%). Patients on fingolimod most commonly discontinued therapy due to either a lack of tolerance or lack of improvement (26.4% and 28.3%, respectively). Patients on natalizumab most commonly discontinued due to a scheduled stop (45.0%), a category that was often used in association with positive John Cunningham virus serology.
When examining the reasons recorded for switching treatments after the introduction of oral therapies (see Table 6 ), a relatively larger proportion of patients switching to fingolimod did so for convenience (10.7%) compared with patients switching to natalizumab (2.6%) or other injectables (6.4%). Patients who stopped their previous therapy due to a lack of improvement, persistence of relapses or progression of disease made up the largest proportion of patients who subsequently commenced natalizumab. Patients were relatively less likely to switch to natalizumab after stopping their previous therapy due to an adverse event or lack of tolerance, and a comparatively small proportion of patients switching to oral therapies switched after pregnancy compared with patients switching to natalizumab or to other injectables.
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Discussion
In this analysis of prospectively collected data from the MSBase registry seen-from-onset cohort, we have shown that patients were more likely to discontinue immunomodulatory therapy once fingolimod became available, while their treatment persistence improved if treated with fingolimod compared with all other DMTs.
We found that 10.5% of patients prescribed fingolimod and between 18.9% and 22.6% of patients prescribed injectable DMTs discontinued treatment within 12 months of initiation. These results are in keeping with discontinuation rates of injectable DMTs reported by other studies. Retrospective American studies have reported 12-month discontinuation rates between 26% and 57%. 8, 9 Prospective European studies investigating long-term adherence to injectable therapies have reported discontinuation rates between 4% over 12 months and 46% over 4.2 years. 10, 11 Given that the MSBase registry is composed of patients from treatment centres across a range of countries around the world, it is important to note that indications for fingolimod prescription differ between countries. While fingolimod is available as a first-line therapy in countries such as Australia, the United States, Switzerland and Kuwait, in all other European Union member countries, including Italy and Spain, fingolimod, similar to natalizumab, is prescribed primarily as a second-line therapy, with first-line indication only for patients with very active disease. Prior MSBase studies, which investigated treatment persistence on two dosages of IFNβ-1a SC, reported annualised discontinuation rates of 25% and 20% for the lower and higher doses, respectively. 4 Another study, which used the MSBASIS cohort to examine first treatment persistence, found that between 31% and 44% of patients discontinued injectable therapy over a median follow-up period between 2.3 years and 3.0 years. 20 To date, the only available study investigating adherence to fingolimod in a real-world setting was published by Agashivala and colleagues. This study used a retrospective pharmaceutical claims dataset with 12 months of follow-up. Among patients living in the United States with previous DMT experience, 26% of those prescribed fingolimod and between 37% and 57% of those prescribed injectable DMTs Table refers to a subset of the study cohort, those patients who discontinued therapy and commenced a different therapy prior the introduction of oral therapies. IFN: interferon; IM: intramuscular; SC: subcutaneous; GA: glatiramer acetate; NAT: natalizumab. Table refers to a subset of the study cohort, those patients who discontinued therapy and commenced a different therapy after the introduction of oral therapies. DMT: disease-modifying therapy; IFN: interferon; IM: intramuscular; SC: subcutaneous; GA: glatiramer acetate; NAT: natalizumab; FTY: fingolimod.
had discontinued therapy over 12 months of follow-up. These results are in agreement with our observation that patients on fingolimod discontinue treatment at a slower rate than patients on injectable DMTs. 15 We have shown that an adverse event or lack of tolerability was the most common reason provided for treatment discontinuation across most of the injectable therapies, the exception being IFNβ-1a IM for which a lack of improvement was the most common reason provided. This finding is consistent with other studies. 5, 21, 22 Agashivala et al. suggested that the better persistence on fingolimod may be attributed to the once daily oral administration and lack of side effects frequently encountered with injectable DMTs, such as influenza-like symptoms and injection site reactions. 15 In our study, the proportion of patients who reported lack of tolerance/adverse event as a reason for fingolimod discontinuation was in the range of that for the injectable DMTs. Here we report that a significantly higher proportion of patients switched to fingolimod, and perhaps persisted on treatment, for convenience (10.7%) when compared with patients switching to injectable therapies or natalizumab. However, this result is limited by the small number of patients who discontinued fingolimod over the follow-up period (71 patients, of whom 53 provided reasons for discontinuation). The most common reason for switching to fingolimod was a lack of improvement on a previous therapy. Given that fingolimod has a second-line indication in a majority of the countries included in this study, this result is not unexpected.
Our study demonstrated that the introduction of fingolimod has changed treatment-switching patterns. In the pre-oral epoch, 73.6% of patients who switched therapies switched to one of the injectable DMTs, while 26.4% of switching patients escalated therapy to natalizumab. These results are consistent with retrospective studies that have looked at treatmentswitching patterns in MS prior to fingolimod introduction, which found that around 25% of patients on injectable therapies escalated to natalizumab. 16, 23 Treatment-switching behaviour was altered considerably in the post-oral epoch, with switching to fingolimod largely replacing the switching between IFN/GA preparations from the pre-oral epoch. Once it became available, 42.3% of switching patients switched to fingolimod, accounting for almost 90% of all fingolimod treatment initiations in our cohort. This reduced the proportion of patients switching to other injectables or natalizumab to 36.6% and 21.1%, respectively, when compared with their pre-oral epoch share.
The relatively smaller decrease in the proportion of patients switching to natalizumab may reflect its higher efficacy, which predisposes it for use in active disease. [24] [25] [26] We have supported this notion by showing that a relatively higher proportion of patients escalated therapy to natalizumab due to ongoing disease activity despite treatment (73.0%).
Female sex, Australian residence, younger age at treatment start, a high EDSS score at treatment commencement and on-treatment relapse activity were additional, independent, predictors of a shorter time to treatment discontinuation. Our finding that country of residence is closely related to treatment persistence, and that females are at a higher risk of discontinuing treatment, replicates and extends prior MSBasis cohort study results. 20 The propensity for females to discontinue therapy at a greater rate than males may be related to childbearing, with a planned or confirmed pregnancy accounting for between 8.5% and 13.4% of all recorded reasons for treatment discontinuation among female patients. This highlights a need for appropriate support and counselling of women planning pregnancy to ensure that they re-engage with treatment as soon as practicable postpregnancy to guard against disability worsening. 27 We further confirmed the findings of prior studies showing that a high EDSS score at treatment commencement is associated with treatment discontinuation. 5, 8 However, here we found that relapse rate on treatment, rather than increasing EDSS score on treatment is associated with a significantly increased risk of treatment discontinuation.
The prospective, observational nature of this study allowed us to follow a well-defined patient cohort representative of clinical practice at tertiary MS centres, over an extended period of follow-up. However, it is important to acknowledge that our data were incomplete in some areas, with a relative lack of MRI data and non-mandatory reporting of reasons for discontinuation. There was also a discrepancy in the proportion of reasons for discontinuation recorded for patients on fingolimod (74.6%) as compared with injectables (52.8%), which could potentially bias our results. Similarly, data on comorbid conditions, which have been shown to affect treatment adherence, 28 are not collected as a mandatory part of the MSBASIS dataset and thus any potential effect could not be assessed. While our analysis had sufficient power to assess our primary endpoint, analysis of the interaction between epoch and other variables may have been underpowered. The observed variability in the length of follow-up between treatment groups is due to their differing periods of availability; similarly, the observed variability in follow-up between countries is due to the differing periods of involvement of the various treatment centres within the MSBASIS study ( Supplementary Table 1 ).
In this study, we have shown that patients with early MS, treated at tertiary MS centres, are more likely to discontinue non-oral therapy in the post-oral epoch, while patients who switch to or initiate fingolimod tend to persist on therapy longer in comparison with patients on injectable DMTs. We speculate that this increased discontinuation rate may be driven by a large proportion of patients finding injectable treatment regimens relatively onerous and subsequently switching to oral DMTs due to their perceived improved tolerability and more convenient route of administration. In this study, we assessed how treatment behaviours have changed with the introduction of the first oral DMT. However further analyses are required to determine whether persistence on fingolimod is superior to that of other oral DMTs once they become more widely available and prescribed. While it is encouraging to see improved treatment persistence in patients taking fingolimod, it remains to be shown if this improved persistence will be associated with improvements in patient outcomes such as disability progression, relapse rate and MRI activity. 
